tbuckley/cabot-search huggingface dataset:
BLOOD PRESSURE FINDINGS IN CIRCULATORY DISORDERS OF THE EXTREMITIES
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Response of rat intracranial 9L gliosarcoma to microbeam radiation therapy
Authors: F.Avraham Dilmanian, Terry M. Button, Géraldine le Duc, Nan Zhong, Louis A. Peña, Jennifer A. L. Smith, Steve R. Martinez, Tigran Bacarian, Jennifer Tammam, Baorui Ren, Peter M. Farmer, John Kalef-Ezra, Peggy L. Micca, Marta M. Nawrocky, James A. Niederer, F.Peter Recksiek, Alexander Fuchs, Eliot M. Rosen
Journal: Neuro-Oncology (2002)

Neuro-OncologyRadiotherapeutic doses for malignant gliomas are generally palliative because greater, supposedly curative doses would impart clinically unacceptable damage to nearby vital CNS tissues.To improve radiation treatment for human gliomas, we evaluated microbeam radiation therapy, which utilizes an array of parallel, microscopically thin (<100 µm) planar beams (microbeams) of synchrotron-generated X rays.Rats with i.c.9L gliosarcoma tumors were exposed laterally to a single microbeam, 27 µm wide and 3.8 mm high, stepwise, to produce irradiation arrays with 50, 75, or 100 µm of on-center beam spacings and 150, 250, 300, or 500 Gy of in-slice, skinentrance, single-exposure doses.The resulting array size was 9 mm wide and 10.4 mm high (using three 3.8-mm
Functional Affinities of Man, Monkeys, and Apes: A Study of the Bearings of Physiology and Behaviour on the Taxonomy and Phylogeny of Lemurs, Monkeys, Apes, and Man
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Environmental Chemical-Induced Macrophage Dysfunction
Authors: L. D. Loose, J. B. Silkworth, T. Charbonneau, F. Blumenstock
Journal: Environmental Health Perspectives (1981)

Immunomodulation by environmental chemical contaminants and the role immune parameters play in toxicity and risk assessment studies is of increasing concern. Although considerable evidence has indicated that various xenobiotics may be immunosuppressive, little attention has been directed toward ascertaining a specific cellular locus which could be responsible for the impaired immune responsiveness. Since previous studies had suggested a macrophage defect in xenobiotic-induced immunosuppression and since macrophages are integral components of an immune response, an in-depth evaluation of macrophage function was conducted in xenobiotic-exposed mice. Macrophages isolated from mice receiving PCB, HCB, and dieldrin had no alteration in their in vitro O2 consumption while at rest or during phagocytosis. In addition, no alteration in in vitro phagocytic activity, phagocytic capacity or microbicidal activity was demonstrated. However, a significant impairment in the in vivo phagocytic clearance of a labelled antigen and an altered tissue distribution of the antigen was observed and was, perhaps, related, in part, to a significant decrease in serum fibronectin, an opsonic alpha 2 surface-binding glycoprotein. Furthermore, animals exposed to HCB and dieldrin, but not to PCB, had a profound decrease in their resistance to a challenge tumor cell implant which was related to a select alteration in tumor cell killing. The adherent spleen cells from HCB-treated mice had a profound suppression in their tumoricidal activity which was in contrast to dieldrin-treated mice, where the target cell type appeared to be the nonadherent cells. However, although dieldrin-exposed adherent cells (macrophages ?) did nt appear to have an altered tumoricidal capacity, all four macrophage types isolated from dieldrin-treated mice had a significantly impaired ability to process a cellular antigen. Splenic and alveolar macrophages appeared to be the most sensitive cell types to dieldrin. The present studies suggest that macrophage dysfunction may be an integral part of xenobiotic-induced immunosuppression and that the effector but not affector component of macrophage function may be the site of alteration.
Chronic Glaucoma with Traumatic Dislocation of Lens
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
EDITORIAI. NOTES.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
For others, methylxanthine withdrawal may work
Journal: JAMA (1980)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mutagenicity Testing of Diethylene Glycol Monobutyl Ether
Authors: Edward D. Thompson, Walter J. Coppinger, Ruby Valencia, Joe Iavicoli
Journal: Environmental Health Perspectives (1984)

The mutagenic potential of diethylene glycol monobutyl ether (diEGBE) was examined with a Tier I battery of in vitro assays followed by a Tier II in vivo Drosophila sex-linked recessive lethal assay. The in vitro battery consisted of: the Salmonella mutagenicity test, the L5178Y mouse lymphoma test, a cytogenetics assay using Chinese hamster ovary cells and the unscheduled DNA synthesis (UDS) assay in rat hepatocytes. Results of the Salmonella mutagenicity test, the cytogenetics test, and the rat hepatocyte assay were negative at concentrations up to 20 microL/plate, 7.92 microL/mL, and 4.4 microL/mL, respectively. Toxicity was clearly demonstrated at all high doses. A weak, but dose-related increase in the mutation frequency (4-fold increase over the solvent control at 5.6 microL/mL with 12% survival) was obtained in the L5178Y lymphoma test in the absence of metabolic activation. Results of the mouse lymphoma assay were negative in the presence of the S-9 activation system. The significance of the mouse lymphoma assay were negative in the presence of the S-9 activation system. The significance of the mouse lymphoma assay results were assessed by performing the Tier II sex-linked recessive lethal assay in Drosophila in which the target tissue is maturing germinal cells. Both feeding (11,000 ppm for 3 days) and injection (0.3 microL of approximately 14,000 ppm solution) routes of administration were employed in the Drosophila assay. Approximately 11,000 individual crosses with an equal number of negative controls were performed for each route of administration. diEGBE produced no increase in recessive lethals under these conditions.(ABSTRACT TRUNCATED AT 250 WORDS)
S 2697: a toxic prescription
Authors: R. Dorsey
Journal: JAMA (1976)

ON Nov 18, 1975, Senators Kennedy and Javits introduced Senate Bill 2697 "to amend the Federal Food, Drug and Cosmetic Act to provide for the continuation and expansion of existing authority through the establishment of an appropriate mechanism to be known as the Drug and Devices Administration, and for other purposes."1 Entitled the "Federal Drug and Devices Act," 2697 would replace the present Food and Drug Administration (FDA) by the Drug and Devices Administration (DDA) and endow the DDA with extensive regulatory power not only over the pharmaceutical industry but over drug prescribing by physicians. Because of three major provisions, the enactment of S 2697 would result in a radical change in public policy with respect to drug marketing and the practice of medicine. These provisions call for (1) the establishment of a "Phase D" evaluation period before final approval of a drug for relatively unrestricted prescribing by physicians, (2)
License in Germany?
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Incorrect Data in the Abstract, Results, Discussion, Limitations, and Table
Journal: JAMA Network Open (2018)

Carolyn T. Lye, BA; Howard P. Forman, MD, MBA; Ruiyi Gao, BS; Jodi G. Daniel, JD, MPH; Allen L. Hsiao, MD; Marilyn K. Mann, JD; Dave deBronkart, BS; Hugo O. Campos; Harlan M. Krumholz, MD, SM
The orange people
Authors: J. D. Hughes
Journal: JAMA (1966)

THE human race comes in various colors: white, yellow, brown, black, and all graduations in between. The American aborigines are described as Red Men and physicians are accustomed to seeing people gray with shock or blue with cyanosis. Yet to see a human as orange as an orange is so startling as to deserve comment—and to see two such cases merits reporting them, especially since no previous emphasis on such bizarre discoloration of patients can be found in medical literature. The parents of orange are the primary colors yellow and red, a fact as old as the history of pigments. Certain foodstuffs have a high content of the yellow pigment carotene, such as carrots and squash; and certain others have a high content of the red pigment lycopene, notably tomatoes and beets. Yellowish discoloration of the skin and other body tissues with carotene is referred to as carotenemia, a not
TEN YEARS' OBSERVATION OF CHILDREN WITH RHEUMATIC HEART DISEASE
Authors: WILLIAM D. STROUD
Journal: JAMA (1933)

From June 1922 to January 1932, at the Children's Heart Hospital in Philadelphia, we have cared for 458 children threatened with or suffering from rheumatic fever and its accompanying cardiovascular damage. In 1925, a summary of our results with 225 children seemed to warrant a continuance of our institution<sup>1</sup>and we reported the reasons for our belief in "the importance of prolonged convalescent care in rheumatic heart disease."<sup>2</sup>We received especial comfort at that time from the following statement by Swift:<sup>3</sup>"A few heart hospitals where proper study of these problems could both intensively and extensively be carried out would do much toward formulating a definite plan in the treatment of a condition which up to the present has been but little permanently benefited by the methods now in vogue." In 1930, we reported our results to date and outlined the requirements for admission and the routine
The significance of immunoglobulin M antibody response to hepatitis C virus core protein in patients with chronic hepatitis C*1
Authors: N YUKI
Journal: Hepatology (1995)

The significance of immunoglobulin (Ig) M antibody to hepatitis C virus core protein (IgM anti-HCVcore) was studied in 41 patients with chronic hepatitis C virus (HCV) infection diagnosed by the polymerase chain reaction (PCR). IgM anti-HCVcore was tested with a solid-phase enzyme-linked immunoassay. The results were correlated with clinical features, liver histology findings evaluated by the histological activity index, and virological features such as genotypes and viremic levels assessed by a branched DNA assay. IgM antiHCVcore was found in 29 (71%) patients, and its occurrence was only related to viremic levels. A significant relationship was observed between viremic levels and IgM anti-HCVcore cut-off index (rs = .42, P < .01). Of the eight low viremic (branched DNA-negative) patients, only two (25%) tested positive for IgM antiHCVcore with a low cut-off index of <3, whereas 27 (82%) of the 33 highly viremic (branched DNA-positive) patients had IgM anti-HCVcore (P < .01). After a 28-week interferon-α course (IFN-α), sustained aminotransferase normalization after therapy withdrawal was achieved by only two (13%) of the 16 patients with IgM anti-HCVcore cut-off index > 3 compared with 11 (44%) of the 25 patients with that <3 (P < .05). IgM anti-HCVcore cut-off index decreased after therapy in patients who cleared the virus in sera but increased again after reappearance of viremia. These findings suggest that IgM anti-HCVcore may serve as a simple serological indicator of active virus replication and have relevance to the outcome of antiviral therapy.
Medical ethics and discipline
Authors: R. C. Derbyshire
Journal: JAMA (1974)

The hospitals, organized medicine, and the state licensing boards are the main agencies responsible for enforcement of discipline in the medical profession, thus guarding the public against unethical and incompetent physicians. These agencies have been critically examined in an effort to determine whether or not they are properly performing their functions. Serious deficiencies have been found in all, and the reasons for them analyzed. Suggestions are made for improving the all important self-policing procedures of the medical profession. (<i>JAMA</i>228:59-62, 1974)
ANESTHESIA IN THE TREATMENT OF BOTULISM
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Genotypic and phenotypic analysis of 34 cases of inherited junctional epidermolysis bullosa caused by <i>COL17A1</i> mutations
Authors: A.L. Hérissé, A. Charlesworth, N. Bellon, S. Leclerc‐Mercier, E. Bourrat, S. Hadj‐Rabia, C. Bodemer, J.P. Lacour, C. Chiaverini
Journal: British Journal of Dermatology (2021)
Primitive Medicine
Authors: M. F. Ashley Montagu
Journal: New England Journal of Medicine (1946)

ANY discussion of so-called "primitive medicine" must begin with an essential clarification. When one speaks of primitive medicine, one refers to a special body of traditional knowledge which compared with that of the present appears crude and undeveloped. It is desirable to remember that this lack of development is a function not of the group's biologic status but of its cultural status, and that its cultural status is, again, a function not of its biologic makeup but primarily of the history of its experience as a social group.The comparatively undeveloped medical knowledge and practice of isolated man is simply . . .
Mitochondrial DNA mutations in colorectal cancer a prognostic and a predictive factor of response to adjuvant chemotherapy
Authors: A. Lievre, C. Chapusot, A.-M. Bouvier, F. Zinzindohoue, F. Piard, J. Faivre, P. Laurent-Puig
Journal: Journal of Clinical Oncology (2004)

9614 Background:Mitochondrial DNA (mtDNA) mutations have been reported in 10% to 70% of colorectal cancers (CRC). Conflicting data on frequency and localization of mtDNA mutations in CRC have been published. Furthermore no data were available on prognostic value of mtDNA mutations. Methods:The aim of this study was to 1) characterize mtDNA mutations in CRC patients 2) search for an association between these mtDNA mutations and tumor phenotype 3) investigate their prognostic value and their role in response to chemotherapy (CT).First, the entire mtDNA was sequenced in normal and tumoral tissues from 11 CRC patients. Then, a 400 bp fragment of the D-Loop was sequenced from tumor mtDNA on a based-population series of 365 colorectal cancer patients treated between 1998 and 2000. Results:Among the 11 patients in whom the entire mtDNA was analyzed, 6 exhibited mtDNA somatic mutations in the D-Loop region, mainly in the D310 repeat (6/8). In the second screening D-Loop mutation was found in 141 of the 365 patients (39%) studied. No association between mtDNA mutation and age, gender, tumor location, tumor stage and tumor MSI status was found. 3-year survival rate of patients without D-Loop mutation was significantly higher than that of patients with D-Loop mutation (62% vs 53%, p= 0.05). In a Cox model, after adjustement for age, tumor stage and tumor MSI status, the RR of death in patients without D-Loop mutation was 0.7 (p<0.04) when compared with those with D-Loop mutation. In the subgroup of stage III colon cancer patients, the presence of a tumor D-Loop mutation was associated with a poor prognosis (3-year survival rate : 42% vs 70%, p<0.02) and was predictive of no response to 5FU-based adjuvant CT. The 3-year survival rate of patients with D-Loop mutation was not improved by CT (41% vs 50%, NS) as it was observed in patients without D-Loop mutation (81% vs 45.5%, p=0.01). Conclusions:the presence of tumor mtDNA mutations, are a prognostic marker and seems to be a relevant predictive factor of no response to adjuvant chemotherapy in patients with stage III colon cancer. These results provide a rationale to evaluate an intensification of adjuvant CT in this setting. No significant financial relationships to disclose.